Table 2.
Disease response to IV and SC IL-15 with haplo-NK-cell infusion
| IV IL-15 | SC IL-15 | P | |
|---|---|---|---|
| No. of evaluable patients | 25 | 15 | |
| Overall response | 8 (32) | 6 (40) | NS |
| CR | 6 (24) | 1 (6) | NS |
| CRi | 2 (8) | 5 (33) | |
| PD | 17 (68) | 9 (60) | |
| NE | 1 | 1 | |
| Overall survival (95% CI) | NS | ||
| 1 y | 19 (7-36) | 21 (5-43) | |
| Median time to death (IQR), mo | 3.68 (2.73-8.37) | 4.93 (1.67-11.47) | |
| Progression-free survival (95% CI) | NS | ||
| 1 y | 12 (3-27) | 19 (5-40) | |
| Median time to progression or death (IQR), mo | 0.93 (0.73-3.83) | 1.05 (0.75-7.72) | |
| No. of patients bridged to alloHSCT | 5 | 6 | NS |
| Median time from transplantation to death (IQR), mo | 24.6 (20.7-28.4) | 14.4 (6.4-22.3) | NS |
All data are n (%), except as noted. Testing for distribution of responses used CR vs CRi vs progressive disease (PD).
NE, not evaluable; IQR, interquartile range; .